Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05066724 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment
A Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT05066724 is a Phase 2 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 50 participants.
The verdict
NCT05066724, a Phase 2 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study will explore the efficacy and tolerability of centanafadine at a dose of 400 mg per day of centanafadine in promoting smoking abstinence in adult smokers seeking to quit.
Interventions
- DRUG Centanafadine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-09-15 |
| Est. Completion | 2022-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05066724
The ClinicalTrials.gov registry entry for NCT05066724 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Centanafadine is the first listed.
NCT05066724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05066724 about?
NCT05066724 is a clinical study titled "Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment". This study will explore the efficacy and tolerability of centanafadine at a dose of 400 mg per day of centanafadine in promoting smoking abstinence in adult smokers seeking to quit.
What is the current status of trial NCT05066724?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2021-09-15. Estimated completion is 2022-05-31.
What interventions are being tested in trial NCT05066724?
The interventions under investigation include: Centanafadine (DRUG).
Who is sponsoring clinical trial NCT05066724?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.